Aorto to alveoli: catastrophic antiphospholipid syndrome masquerading as multisystem failure
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261724Keywords:
Catastrophic APS, Diffuse alveolar haemorrhage, Haemothorax, Multiorgan thrombosis, β2-glycoproteinAbstract
Catastrophic Antiphospholipid Syndrome (CAPS) is a rare, fulminant variant of antiphospholipid syndrome, characterized by rapid multi-organ involvement due to widespread thrombosis. We report a 65-year-old male, with prior comorbidities such as diabetes, hypertension, dyslipidemia, cerebrovascular accident and coronary artery disease who presented with complete thrombosis of the distal abdominal aorta and common iliac vessels. During hospital stay, he developed acute respiratory distress, right-sided haemothorax with massive pleural effusion, diffuse alveolar haemorrhage, acute kidney injury with microscopic haematuria, and neurological deterioration requiring mechanical ventilation. Initial autoimmune workup was negative for ANA, ANCA, and anti-GBM antibodies. However, β2-glycoprotein IgG was strongly positive, and anticardiolipin antibody was borderline positive, raising suspicion of CAPS. Given the constellation of multiorgan dysfunction with diffuse alveolar haemorrhage and vascular thrombosis, a diagnosis of catastrophic APS was considered. The patient underwent aggressive multimodal therapy including pulse corticosteroids, anticoagulation, renal replacement therapy, immunomodulators, and ventilatory support. Plasma exchange/IVIG was planned in case of further worsening. With multidisciplinary management and intensive supportive care, the patient showed gradual recovery, and was discharged in a stable condition. This case highlights the diagnostic challenge of CAPS, which often masquerades as vasculitis, sepsis, or other autoimmune diseases. It also underlines the management hurdles, requiring timely recognition, multidisciplinary coordination, and combined immunosuppression and anticoagulation. Despite its rarity, CAPS should be considered in patients with rapidly progressive multiorgan thrombosis, as early diagnosis and intervention can be life-saving.
Metrics
References
Asherson RA, Cervera R, De Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530-4. DOI: https://doi.org/10.1191/0961203303lu394oa
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev. 2006;6(2):72-5. DOI: https://doi.org/10.1016/j.autrev.2006.06.007
Erkan D, Lockshin MD. APS and catastrophic APS: diagnosis and management. Best Pract Res Clin Rheumatol. 2020;34(1):101463.
Cervera R, Rodríguez-Pintó I, Espinosa G. Catastrophic antiphospholipid syndrome: task force report summary. Autoimmun Rev. 2014;13(7):699–707. DOI: https://doi.org/10.1016/j.autrev.2014.03.002
Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum. 2015;45(3):369-74. DOI: https://doi.org/10.1016/j.semarthrit.2014.10.013
Loza G, Hallo C, Chiliquinga B, Hallo A. Alveolar hemorrhage, a rare and lifethreatening complication of catastrophic antiphospholipid syndrome. Case Rep Rheumatol. 2019;2019:1-4. DOI: https://doi.org/10.1155/2019/3284258
Rahman A, Nathani M, Malekan M. The relentless recurrence of diffuse alveolar hemorrhage in catastrophic antiphospholipid syndrome and lupus: a therapeutic challenge. Cureus. 2024;16(2):e57462. DOI: https://doi.org/10.7759/cureus.62635
Seth I, Srinivasan SPB, Bulloch G, Yi DS, Frankel A, Hsu K, et al. Diffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome. Respirol Case Rep. 2022;10(5):e0948. DOI: https://doi.org/10.1002/rcr2.948
Harrison TR. Harrison’s Principles of Internal Medicine. 21st ed. New York: McGraw-Hill. 2022.
Espinosa G, Rodríguez-Pintó I, Gómez-Puerta JA, Pons-Estel G, Cervera R. Relapsing CAPS: report from the CAPS Registry. Rheumatology. 2013;52(1):111-7.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75(10):1687-702. DOI: https://doi.org/10.1002/art.42624
Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28(3):218-27. DOI: https://doi.org/10.1097/BOR.0000000000000269